Clinical-grade preventive intelligence
BioTwin aims to equip primary care and frontline clinics with AI-powered screening protocol research to support medical decision and stratify risk across 5 clinical domains and 15 health conditions. From simple at-home collection.
Patients join the journey through TwinMe, our consumer app for personalized health tracking.
BioTwin multi-omics approach integrates biological analysis, complete lifestyle & medical data into actionable clinical insights — enabling screening, longitudinal monitoring, and decision-support research outputs.
Current healthcare often intervenes too late, treats populations instead of individuals, and leaves prevention to chance.
No unified protocol covers multiple disease domains at once. Clinicians juggle disconnected screening tools with no shared view.
People only engage the system when symptoms appear. By then, early intervention windows have closed.
Comprehensive screening programs are expensive, time-consuming, and hard to repeat. Most clinics can't offer it at scale.
BioTwin integrates multi-omics and AI-driven models in research and pilot studies to explore how virtual twins can support future clinical decision tools.
AI-powered screening protocol research, unified dashboards, longitudinal monitoring, and structured triage support across 5 domains.
Through TwinMe, patients access their health data, track their progress, and stay connected to their care team.
BioTwin is being validated through clinical research and pilot collaborations, designed as a clinical decision-support (CDST) layer that augments physician judgment with longitudinal, multi-omic insights. It does not replace clinicians or provide standalone diagnoses. BioTwin is currently in research and validation phase and is not yet a clinically validated medical solution.
5 clinical domains. 15 health conditions.
BioTwin protocol aims to monitor biological signals, screen for meaningful deviations from each individual's baseline, and flag risk supporting clinical, triage and routing decisions. BioTwin does not replace physicians. BioTwin aims to provide a longitudinal decision-support research layer that strengthens primary-care workflows and reduces uncertainty, latency and diagnostic burden.
Flags early biological risk signals to support imaging and referral prioritization.
Multi-Cancer Early Detection (MCED)Helps flag early biological risk, including where no screening exists
Helps refine imaging, biopsy, and referral prioritization
Helps support surveillance and recurrence monitoring decisions
Supports earlier specialist triage before overt symptoms appear.
Helps identify early biological risk before overt symptoms
Helps support specialist referral and diagnostic triage pathways
Helps monitor progression and treatment response longitudinally
Highlights elevated cardiac risk for faster follow-up and intervention planning.
Helps flag elevated risk before acute events or decompensation
Helps support referral, imaging, and therapy optimization decisions
Helps monitor biological response to treatment over time
Tracks hidden metabolic decline and personalizes lifestyle action.
Track hidden metabolic and performance decline early
Personalize intervention intensity before complications emerge
Track whether lifestyle and therapy changes actually work
Transforms biological drift into proactive healthspan decisions.
Extends healthspan through continuous trajectory optimization
Detects early multi-system decline before disease onset
Converts biological drift into proactive healthspan action
Clinical decision-support research tool — not a diagnostic replacement. Currently in validation phase.
The BioTwin 5-10-15 Protocol aims to deliver a comprehensive biological scan of you, powered by your personal virtual twin. It combines multi-omic analysis (genomic, proteomic, metabolomic biomarkers), clinical and lifestyle assessments, and continuous data from wearables, apps, imaging, and medical records, alongside facial, skin, voice, and movement biomarkers. All signals aim to be unified into a continuously updated virtual twin, providing a 360-degree view of your health and how it evolves over time, not a one-time snapshot. 5 days. 10 drops. 15 health conditions.
Simple & effortless samples collection over 5 days, flexible to fit your schedule and capture biological variability.
Low-friction at-home collection using finger blood, urine, and saliva. No clinic visit required.
One unified view across five clinical domains: Oncology, Neurology, Cardiology, Lifestyle, and Life & Health Span.
Single measurements capture only a snapshot.
BioTwin's repeat sampling builds a personal biological baseline and detects meaningful change earlier — enabling smarter decisions over time.
| BioTwin | One-off Tests | Wellness Platforms | |
|---|---|---|---|
| Approach | Longitudinal virtual twin modeling | Single snapshot testing | Periodic biomarker panels |
| Scope | Multi-domain health conditions | Single condition focus | General wellness metrics |
| Clinical integration | Clinician-integrated decision support | Standalone result delivery | Coaching only |
| Output | Structured routing logic | Signal detection only | Descriptive reports |
BioTwin's approach is grounded in peer-reviewed biomedical research supporting longitudinal profiling, multi-omic integration, and virtual twin modeling for improved clinical risk stratification.
Multi-omic and liquid biopsy research supports blood-based risk stratification and referral optimization across major cancers.
Plasma biomarker and proteomic research supports earlier biological signal identification in neurodegenerative and mood disorders.
Guideline-embedded biomarkers combined with omic profiling enhance cardiovascular risk stratification beyond single measurements.
Large-scale metabolomic research demonstrates predictive biological signatures preceding metabolic disease onset.
Proteomic and metabolomic aging research demonstrates reproducible associations with healthspan and long-term disease risk.
Prepare for 2027 pilot deployment
Limited onboarding slots for primary-care partners
Begin collecting your biological baseline now. Protocol activation in 2027.